Evidence map›Paper›PMID 26150150›Full record

ArticleThe Journal of molecular diagnostics : JMD2015

Interferon λ 3 and 4 Genotyping Using High-Resolution Melt Curve Analysis Suitable for Multiple Clinical Sample Types.

François M J Lamoury, Sofia Bartlett, Brendan Jacka, Behzad Hajarizadeh, Jason Grebely, Gail V Matthews, Gregory J Dore, Tanya L Applegate

Open access · bronzeAbstract readValidation Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

François M J LamouryViral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales Australia, Sydney, Australia. Electronic address: flamoury@kirby.unsw.edu.au.
Sofia BartlettViral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales Australia, Sydney, Australia.
Brendan JackaViral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales Australia, Sydney, Australia.
Behzad HajarizadehViral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales Australia, Sydney, Australia.
Jason GrebelyViral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales Australia, Sydney, Australia.
Gail V MatthewsViral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales Australia, Sydney, Australia; HIV/Immunology/Infectious Diseases Clinical Services Unit, St. Vincent's Hospital, Sydney, Australia.
Gregory J DoreViral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales Australia, Sydney, Australia; HIV/Immunology/Infectious Diseases Clinical Services Unit, St. Vincent's Hospital, Sydney, Australia.
Tanya L ApplegateViral Hepatitis Clinical Research Program, The Kirby Institute, University of New South Wales Australia, Sydney, Australia.
UNSW Sydney · AU

Funding

Treatment of recently acquired hepatitis C virus infectionR01DA015999 · NIDA · UNIVERSITY OF NEW SOUTH WALES · PI DORE, GREGORY JOHN · 2003 to 2014
$3.7M
NIDA NIH HHS R01 DA015999
6 · The paper itself

Abstract

Many people living with hepatitis C virus (HCV) infection will continue to rely on interferon-based regimens until effective strategies to minimize the cost of directly acting antivirals (DAAs) and to improve treatment access are implemented. Host single-nucleotide polymorphisms related to IFNL3 and IFNL4 are associated with spontaneous clearance of HCV, and pegylated interferon- and DAA-based treatment outcomes. We describe a simple and rapid genotyping method for IFNL rs12979860, rs8099917, and rs368234815 using high-resolution melting analysis for DNA extracted from whole blood, buffy coat, plasma, serum, and dried blood spots. This assay successfully detected all three polymorphisms on DNA extracted by the automated platform easyMAG from all samples when compared to sequenced amplicons. Analysis of 126 participants with recent HCV infection from the Australian Trial in Acute Hepatitis C study demonstrated the prevalence of favorable single-nucleotide polymorphisms were 62%, 51%, and 45% for rs8099917 TT, rs12979860 CC, and rs368234815 TT/TT, respectively. The genotyping assay described here provides a rapid and affordable IFNL3 and IFNL4 genotyping method for a range of clinical sample types. Until global access to DAAs is achieved, IFNL3 and IFNL4 genotyping could identify those likely to clear naturally and in whom treatment could be delayed, or help prioritize DAA treatment to those less likely to respond to interferon-containing regimens.

Indexed as

Polymorphism, Single NucleotideAcute DiseaseBlood CellsDNAGenotypeGenotyping TechniquesHepatitis CHumansInterferon LambdaInterferonsInterleukinsNucleic Acid DenaturationDNAIFNL4 protein, humanInterferon Lambdainterferon-lambda, humanInterferonsInterleukins

Identifiers

PMID26150150
PMCPMC4597282
OpenAlexW1507450483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.